生物制剂及靶向合成DMARDs治疗中轴型脊柱关节炎的有效性与安全性:系统文献综述(为2016年ASAS/EULAR推荐更新提供依据)
该系统文献综述纳入2009–2016年随机对照试验、长期扩展研究、策略试验及观察性研究(仅安全性评估需设对照),评估bDMARD或tsDMARD在axSpA中的疗效与安全性。结果显示TNFi在r-axSpA和nr-axSpA中均有显著疗效,司库奇尤单抗150 mg在两项3期RCT中有效,乌司奴单抗和托法替布在2期/概念验证试验中阳性,而阿普斯特、利妥昔单抗、IL-6拮抗剂和阿巴西普试验未达主要终点。未发现新的安全性信号,但TNFi长期观察性安全性数据仍匮乏。
要点
- TNFi在r-axSpA和nr-axSpA中均显示大疗效,nr-axSpA中客观炎症证据者疗效更优。
- 司库奇尤单抗150 mg是首个在r-axSpA中显示有效的IL-17通路药物。
- 阿普斯特、利妥昔单抗、IL-6拮抗剂和阿巴西普试验未达主要终点。
核心结论
- 新证据支持TNFi在r-axSpA和nr-axSpA中的疗效与安全性。
- 司库奇尤单抗是首个在r-axSpA中显示有效的靶向IL-17通路药物。
研究设计与样本
- 系统文献综述(2009–2016年),纳入随机对照试验(含长期扩展)、策略试验及观察性研究(仅用于安全性评估且需设对照)。
- 干预措施为任何bDMARD或tsDMARD,共纳入76篇论文和24篇摘要。
主要发现
- 所有TNFi在r-axSpA和nr-axSpA中均显示大疗效,达到ASAS40反应的NNT在r-axSpA为2.6–5.2,在nr-axSpA为2.3–5.4。
- nr-axSpA中,有客观炎症证据(C反应蛋白阳性或MRI-SI炎症)者疗效更优。
- 司库奇尤单抗150 mg在两项3期RCT中显示疗效,达到ASAS40反应的NNT分别为3.4和4.0。
- 乌司奴单抗和托法替布在2期/概念验证试验中显示阳性结果。
- 阿普斯特、利妥昔单抗、IL-6拮抗剂和阿巴西普试验未达主要终点。
关键数值与推荐
- TNFi达到ASAS40反应的NNT:r-axSpA为2.6–5.2,nr-axSpA为2.3–5.4。
- 司库奇尤单抗150 mg达到ASAS40反应的NNT:3.4和4.0(两项3期RCT)。
临床怎么用
- TNFi可用于r-axSpA和nr-axSpA,nr-axSpA患者优先考虑有客观炎症证据者。
- 司库奇尤单抗150 mg可作为r-axSpA的IL-17通路靶向治疗选择。
局限性
- TNFi的长期观察性安全性数据仍匮乏。
- 观察性研究仅用于安全性评估且需设对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required). Interventions were any bDMARD or tsDMARD. All relevant efficacy and safety outcomes were included. RESULTS: 76 papers and 24 abstracts fulfilled the inclusion criteria. Large treatment effects were found both in radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) for all tumour necrosis factor inhibitors (TNFi) (NNT to achieve ASAS40 response ranged between 2.6-5.2 for r-axSpA and 2.3-5.4 for nr-axSpA). For nr-axSpA, efficacy was superior for those who had objective signs of inflammation (positive C reactive protein or inflammation on MRI-SI). Secukinumab 150 mg has shown efficacy in two phase 3 RCTs (NNT to achieve ASAS40 response: 3.4 and 4.0). Ustekinumab and tofacitinib have shown positive results in phase 2/proof-of-concept trials; trials with apremilast, rituximab, interleukin (IL)-6 antagonists and abatacept have failed their primary end points. New (unknown) safety signals were not found in the trials but long-term observational safety data for TNFi are still scarce. CONCLUSIONS: New evidence supports the efficacy and safety of TNFi both in r-axSpA and nr-axSpA. Secukinumab is the first drug targeting the IL-17 pathway in r-axSpA that has shown efficacy.
引用
- Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017. PMID: 28176964. doi:10.1136/rmdopen-2016-000396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。